Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Laxxon Medical reports positive results from pilot PK study of innovative oral GLP-1 agonist weight loss tablet, LXM.2 ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...

Novo NOrdisk (NVO) stock drops as Medicare selects 15 additional Part D drugs including its weight loss drug Wegovy for ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...